文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血流感染患者抗生素治疗7天与14天的比较

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.
PubMed 文献 · N Engl J Med · 2024-11-20
一句话结论在住院血流感染患者中,7天抗生素治疗非劣于14天治疗(90天死亡率差异-1.6个百分点,95.7%CI -4.0至0.8)。

这项多中心非劣效性试验随机分配3608例住院血流感染患者(含ICU患者)接受7天或14天抗生素治疗,抗生素选择、剂量和途径由治疗团队决定。排除严重免疫抑制、需延长治疗的病灶、单次培养可能为污染菌或培养出金黄色葡萄球菌的患者。主要终点为诊断血流感染后90天全因死亡,非劣效界值为4个百分点。7天组90天死亡14.5%,14天组16.1%,差异-1.6个百分点(95.7%CI -4.0至0.8),显示短期治疗非劣效;符合方案分析同样显示非劣效(差异-2.0个百分点,95%CI -4.5至0.6)。

要点

  • 在74家医院、7个国家的3608例住院血流感染患者中,7天组90天死亡14.5%(261例),14天组16.1%(286例),差异-1.6个百分点(95.7%CI -4.0至0.8),达到非劣效。
  • 符合方案分析支持非劣效:7天组与14天组死亡差异-2.0个百分点(95%CI -4.5至0.6)。
  • 入组时55.0%患者在ICU、45.0%在普通病房;感染来源以尿路(42.2%)、腹腔(18.8%)、肺部(13.0%)最常见。
  • 7天组23.1%患者实际治疗超过分配时长,14天组为10.7%。
  • 次要临床结局和预设亚组(患者、病原体、综合征特征)结果总体一致。

适用人群与场景

  • 住院血流感染患者,包括ICU患者;入组时55.0%在ICU、45.0%在普通病房。
  • 感染获得场所:社区75.4%、医院病房13.4%、ICU 11.2%。
  • 排除严重免疫抑制、需延长治疗的病灶、单次培养可能为污染菌、培养出金黄色葡萄球菌的患者。

诊断标准与关键阈值

  • 主要终点为非劣效性检验,非劣效界值为4个百分点。

处置流程与药物剂量

  • 随机分配至抗生素治疗7天或14天;抗生素选择、剂量和途径由治疗团队决定。

研究设计与关键结果

  • 多中心、非劣效性随机试验,74家医院、7个国家,3608例患者纳入意向性分析(7天组1814例,14天组1794例)。
  • 90天全因死亡:7天组14.5%(261例)vs 14天组16.1%(286例),差异-1.6个百分点(95.7%CI -4.0至0.8),显示7天治疗非劣效。
  • 符合方案分析:差异-2.0个百分点(95%CI -4.5至0.6),同样显示非劣效。
  • 实际治疗超过分配时长:7天组23.1%,14天组10.7%。
  • 次要临床结局及预设亚组(患者、病原体、综合征特征)结果总体一致。
  • 血流感染最常见来源:尿路42.2%、腹腔18.8%、肺部13.0%、血管导管6.3%、皮肤软组织5.2%。

证据类型、等级与局限

  • 证据类型:多中心、非劣效性随机对照试验(BALANCE,NCT03005145)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于住院血流感染患者(包括ICU患者),7天抗生素治疗非劣于14天治疗;该结论不适用于严重免疫抑制、需延长治疗的病灶、单次培养可能为污染菌或培养出金黄色葡萄球菌的患者。

指南或共识出处

  • BALANCE试验,ClinicalTrials.gov注册号NCT03005145;由加拿大卫生研究院等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain.

METHODS: In a multicenter, noninferiority trial, we randomly assigned hospitalized patients (including patients in the intensive care unit [ICU]) who had bloodstream infection to receive antibiotic treatment for 7 days or 14 days. Antibiotic selection, dosing, and route were at the discretion of the treating team. We excluded patients with severe immunosuppression, foci requiring prolonged treatment, single cultures with possible contaminants, or cultures yielding Staphylococcus aureus. The primary outcome was death from any cause by 90 days after diagnosis of the bloodstream infection, with a noninferiority margin of 4 percentage points.

RESULTS: Across 74 hospitals in seven countries, 3608 patients underwent randomization and were included in the intention-to-treat analysis; 1814 patients were assigned to 7 days of antibiotic treatment, and 1794 to 14 days. At enrollment, 55.0% of patients were in the ICU and 45.0% were on hospital wards. Infections were acquired in the community (75.4%), hospital wards (13.4%) and ICUs (11.2%). Bacteremia most commonly originated from the urinary tract (42.2%), abdomen (18.8%), lung (13.0%), vascular catheters (6.3%), and skin or soft tissue (5.2%). By 90 days, 261 patients (14.5%) receiving antibiotics for 7 days had died and 286 patients (16.1%) receiving antibiotics for 14 days had died (difference, -1.6 percentage points [95.7% confidence interval {CI}, -4.0 to 0.8]), which showed the noninferiority of the shorter treatment duration. Patients were treated for longer than the assigned duration in 23.1% of the patients in the 7-day group and in 10.7% of the patients in the 14-day group. A per-protocol analysis also showed noninferiority (difference, -2.0 percentage points [95% CI, -4.5 to 0.6]). These findings were generally consistent across secondary clinical outcomes and across prespecified subgroups defined according to patient, pathogen, and syndrome characteristics.

CONCLUSIONS: Among hospitalized patients with bloodstream infection, antibiotic treatment for 7 days was noninferior to treatment for 14 days. (Funded by the Canadian Institutes of Health Research and others; BALANCE ClinicalTrials.gov number, NCT03005145.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Daneman N, Rishu A, Pinto R, et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. 2024. PMID: 39565030. doi:10.1056/NEJMoa2404991

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。